About Orchid
Orchid is a company based in Armadale (Australia) founded in 2019. It operates as a HealthTech. Orchid has raised $16.5 million across 2 funding rounds from investors including 23andMe, LIfT Biosciences and Prometheus Fund. Orchid offers products and services including Embryo Report and Couple Report. Orchid operates in a competitive market with competitors including Immunosis, The Gene Council, Genepath and Private Genetic Health, among others.
- Headquarter Armadale, Australia
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$16.5 M (USD)
in 2 rounds
-
Latest Funding Round
$12 M (USD), Series A
Dec 05, 2023
-
Investors
23andMe
& 16 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orchid
Orchid offers a comprehensive portfolio of products and services, including Embryo Report and Couple Report. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Advanced genetic screening for embryos during IVF process.
Preconception test for child’s genetic disease predisposition.
Unlock access to complete
Unlock access to complete
Funding Insights of Orchid
Orchid has successfully raised a total of $16.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $12.0M
-
First Round
First Round
(07 Apr 2021)
- Investors Count 17
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Series A - Orchid | Valuation | Prometheus Fund | |
| Apr, 2021 | Amount | Seed - Orchid | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Orchid
Orchid has secured backing from 17 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include 23andMe, LIfT Biosciences and Prometheus Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment fund focused on undervalued securities is managed.
|
Founded Year | Domain | Location | |
|
Seed and early-stage investments are made across US and India.
|
Founded Year | Domain | Location | |
|
Technical founders are supported by Pebblebed through early investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Orchid
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Orchid
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Orchid Comparisons
Competitors of Orchid
Orchid operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Immunosis, The Gene Council, Genepath and Private Genetic Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of a diagnostic platform for diagnosing patients with immune dysfunctions
|
|
| domain | founded_year | HQ Location |
Offers private genetic testing and counselling for cancer risk, with online appointments and expert advice.
|
|
| domain | founded_year | HQ Location |
Provides targeted gene sequencing for newborn screening and health detection.
|
|
| domain | founded_year | HQ Location |
Provides genetic counselling, testing, and education for families with health conditions.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Orchid
Frequently Asked Questions about Orchid
When was Orchid founded?
Orchid was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Orchid located?
Orchid is headquartered in Armadale, Australia. It is registered at Armadale, Victoria, Australia.
Is Orchid a funded company?
Orchid is a funded company, having raised a total of $16.5M across 2 funding rounds to date. The company's 1st funding round was a Seed of $4.5M, raised on Apr 07, 2021.
What does Orchid do?
Whole genome screening for embryos during IVF is offered by Orchid to detect genetic risks for severe diseases before pregnancy. Services include the Embryo Report for advanced genetic screening and the Couple Report for preconception genetic predisposition testing. Risks for monogenic and polygenic diseases, neurodevelopmental disorders, cancers, and birth defects are identified using over 99 of an embryos DNA data. Solutions are tailored for patients and clinicians in the reproductive health sector.
Who are the top competitors of Orchid?
Orchid's top competitors include Immunosis, The Gene Council and Genepath.
What products or services does Orchid offer?
Orchid offers Embryo Report and Couple Report.
Who are Orchid's investors?
Orchid has 17 investors. Key investors include 23andMe, LIfT Biosciences, Prometheus Fund, Refactor Capital, and Pebblebed.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.